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Background: Aromatase inhibitors (AIs) have been used in boys with idiopathic short
stature (ISS) to promote growth despite the lack of actual data regarding treatment effect
on adult height. In this study, we characterized adult heights and long-term follow-up in
AI-treated boys with ISS.
Methods: Adult heights and long-term follow-up data, including spine MRIs, of
a randomized, double-blind, placebo-controlled trial of boys who were treated with
letrozole (Lz) (2.5 mg/d) or placebo (Pl) for 2 years during prepuberty and early puberty.
The mean bone ages at treatment cessation were 10.2 and 10.8 years, respectively.
Results: Adult heights were similar between the boys treated with Lz (n= 10) and those
who received Pl (n= 10) (164.8± 4.0 vs. 163.7± 3.7 cm, p= 0.49, respectively). In either
group, the adult heights did not differ from predicted adult heights at start of the study
[Pl: 163.7 (3.7) cm vs. 166.9 (3.3), p= 0.06; Lz: 164.8 (4.0) cm vs. 167.6 (7.9), p= 0.20,
respectively]. Long-term follow-up data showed that the frequency of subjects with a
vertebral deformity was similar between the groups (Lz, 29% and Pl, 22%, p = 0.20),
and no single comorbidity was clearly enriched in either group.
Conclusions: The Lz-treated boys had similar adult heights with the subjects who
received Pl for 2 years, which indicates that the treatment is not beneficial when given to
pre- or early-pubertal boys. Previously observed vertebral deformities ameliorated during
follow-up, which supports the skeletal safety of Lz therapy in children and adolescents.
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INTRODUCTION
Third generation aromatase inhibitors (AIs), such as letrozole (Lz) and anastrozole, are compounds
that effectively suppress estrogen biosynthesis and have been shown to delay bone maturation in
boys with growth hormone deficiency (GHD), constitutional delay of growth and puberty (CDGP),
and idiopathic short stature (ISS) (1–4). The treatment with AIs has resulted in an increased
predicted adult height (PAH) after 1–3 years of treatment (1, 3, 5, 6). These promising results
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have prompted the interest of using AIs for growth indications
in adolescent boys (7, 8), albeit the long-term efficacy of the
treatment on height gain lacks verification, since adult height
data from controlled trials of AI-treated boys is limited to one
study that included 6 boys with CDGP who received Lz for 1
year during mid-puberty (9). Furthermore, the long-term safety
of blocking estrogen biosynthesis during childhood is unclear
(7), particularly regarding the influence of AI-treatment on
skeletal health (9). The concerns that long-term use of AIs might
be detrimental to spine vertebral morphology stem from our
previous report that shows an increased risk of mild vertebral
deformities of unknown clinical significance in boys treated with
Lz prior to the onset of puberty (9).
The short-term efficacy and safety data of AI-treatment in
adolescents are reassuring (1, 3, 4), but the availability of long-
term data is extremely limited. In fact, the lack of evidence has
resulted in confusion and differing views on the off-label use
of such treatment in growth indications, varying from relatively
liberal use in pubertal short boys to strictly limited pediatric use
in clinical studies pending long-term efficacy and safety results
from randomized controlled trials (7, 8, 10, 11).
In this study, we report adult heights and long-term follow-
up data, including spine health assessed with magnetic resonance
imaging (MRI), in boys with ISS who were treated with either Lz
or placebo (Pl) for 2 years during prepuberty or early puberty.
MATERIALS AND METHODS
The study population included 30 pre- and early-pubertal
boys with ISS who participated in a randomized, double-blind,
placebo-controlled study, in which the boys were treated with
either Lz (2.5 mg/d, n = 16) or Pl (n = 14) for 2 years in an
attempt to increase adult height (1). When the study started,
little was known about the optimal timing of the treatment in
this target population, and prepubertal boys who were expected
to progress in puberty in the near future were permitted to
participate. For this study, the boys were contacted once more
and asked to participate in a final study visit in order to measure
adult heights and to evaluate long-term effects of the treatment.
Seventeen of the 30 boys (57%), 8 of whom were treated with
Lz and 9 with Pl, agreed to come to the adult height visit, and
were evaluated in the pediatric endocrinology outpatient clinic at
the Helsinki University Hospital (HUH) between 2012 and 2017.
Additionally, we included the height measurements of three boys
(two with Lz and one with Pl) who were at near adult height
at the post-treatment follow-up visit (9). These boys had bone
ages of more than 17 years, and, consequently, had used over
98% of their growth potential (12). Thus, the overall number
of patients with adult height or near adult height was 20 (67%,
n = 10 in each group). All the boys in the Pl group and eight
boys in the Lz group were prepubertal at the beginning, and,
after the treatment, twelve of the 20 boys (seven with Pl and five
with Lz) were pubertal. Baseline characteristics and distribution
of Tanner genital stages at the beginning of the study and at the
treatment cessation are shown in Table 1. The mean bone ages
at treatment cessation were 10.2 and 10.8 years in Lz and Pl
TABLE 1 | Characteristics of the participants with adult height or near adult height
data.
Lz (n = 10) Pl (n = 10)
AT THE START OF THE STUDY
Height (cm) 129.7 (7.9) 127.5 (7.5)
Height (SDS) −2.4 (0.3) −2.5 (0.4)
Age (years) 11.5 (1.8) 10.9 (1.8)
Bone age (years) 9.2 (2.6) 8.7 (1.9)
Testicular volume 1.5 (1.4) 1.0 (0.6)
Testosterone level (nmol/l) 1.4 (1.9) 0.4 (0.4)
AT THE ADULT HEIGHT VISIT
Height (cm) 164.8 (4.0) 163.7 (3.7)
Height (SDS) −2.6 (0.7) −2.7 (0.7)
Age (years) 23.3 (4.0) 21.7 (3.1)
Bone age (years) 18.5 (0.7) 18.7 (0.7)
Testicular volume (ml) 12.8 (3.0) 12.2 (3.5)
BMI (kg/m2) 22.1 (3.2) 23.8 (5.4)
PAH at the start of the study (cm) 167.6 (7.9) 166.9 (3.9)
PAH after 2 years of treatment (cm) 174.0 (8.3) 167.4 (4.3)a*
Change in PAH during treatment (cm) 6.4 (2.2) 0.5 (4.4)b
Bone age after 2 years of treatment (years) 10.2 (2.9) 10.8 (1.5)
Tanner G-stage of puberty at the start of the
study, distribution from G1 through 5, (n)
8/2/0/0/0 10/0/0/0/0
Tanner G-stage of puberty at treatment
cessation, distribution from G1 through 5, (n)
5/0/1/1/3 3/3/2/2/0
Mean (SD). ap = 0.049, bp = 0.004. P-values are for between group comparisons.
*The difference remained significant in the subgroup of 17 boys with complete skeletal
maturation [Lz: 174.9 (9.1), Pl 167.5 (4.5), p= 0.047]. The difference remained significant
in the subgroup of 17 boys with complete skeletal maturation [Lz: 6.8 (2.3), Pl 0.1 (4.5),
p = 0.002]. PAH, predicted adult height by Bayley-Pinneau (12).
groups, respectively. Predicted adult heights were calculated by
the Bayley-Pinneau method (12), which produces a percentage of
height attained relative to final height.
At the adult height visit, weight wasmeasured with a stabilized
and calibrated scale (Seca R© 878dr) and height with a calibrated,
wall-mounted Harpender stadiometer with 0.1 cm precision or,
inminority of patients (n= 5), portable stadiometer (Seca R© 213).
Subjects were interviewed, and chronic diseases and medication
were recorded. Pubertal stage was determined and testicular
volume (ml) was calculated by using the formula: length (cm)
× width2 (cm) × 0.52 (13). In all boys, puberty was complete
as evaluated with Tanner genital and pubic hair stages (14).
In addition, we reviewed the medical records of the 30 boys
who participated in the original study and collected information
regarding co-morbidities that had required medical attention
(1). Mid-parental target height was calculated by using the
formula: 0.886 × [(father’s height + mother’s height)/2 + 6.8–
178.9066]/6.6784–0.071.
Spine health was re-evaluated by MRI in 12 subjects at the
adult height visit. Additionally, we included the MRI findings
of four patients from the post-treatment visit, since these boys
had had bone age of more than 17 years (9). Spine MRIs
were performed with a 1.5 T imager (Intera Achieva, Philips
Medical Systems, Best, Netherlands) using a total-spine imaging
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protocol and analyzed as described before (9). In detail, special
interest was paid on vertebral body anatomy, endplates, disk
height, and muscle status. The MRI images were evaluated by
experienced radiologists (ST-S and LK), who were blinded to the
treatment modality. At the adult height visit, vertebral anatomy
was classified by using the classification for pediatric vertebral
body morphology (15), since it enabled the comparison of the
results to the MRI findings from the post-treatment visit (9).
In detail, vertebral anterior and middle wedge deformities were
classified as mild (grade 2a) if the reduction in anterior height
was between 20 and 50%, and severe (grade 2b) if it was more
than 50%. Compression deformities were classified into mild
(grade 3a) and severe (grade 3b), if the reductions in anterior,
middle, and posterior height were between 20 and 50% or >50%,
respectively. The back muscle status was evaluated by measuring
the average psoas muscle thickness (mm).
The study was reviewed and approved by HUH and the
Ethics Committee of HUH, and a written informed consent was
obtained from all the participants. The study was performed
according to the Declaration of Helsinki.
Statistical Analyses
The data were analyzed by using SPSS statistical software for
Windows, version 22.0 (SPSS, Chicago, IL, USA). The results
are presented with mean (standard deviation) unless otherwise
mentioned. The comparisons between the two groups were
performed with Mann-Whitney U-test and with Fisher’s exact
test. Adult or near adult heights were compared with PAHs
at the beginning of the study (1) and at the post-treatment
visit (9, 15) and with target heights by using Wilcoxon signed-
rank test. Spearman rank correlations were calculated. Number
needed to harm (NNH) with Lz-treatment was calculated for the
risk of vertebral deformity. Statistically significant level was set
to p < 0.05.
RESULTS
Adult Height
The clinical and auxological data did not differ between the
treatment groups and are detailed in Table 1. The boys who were
treated with Lz (n= 8) had similar adult heights with the subjects
who received Pl (n = 9) [164.7 (4.6) vs. 163.2 (3.5) cm, p = 0.47,
respectively]. In addition, when comparing the boys who had
reached adult height or near adult height (n= 20), no differences
were found between the groups [Lz: 164.8 (4.0) and Pl: 163.7 (3.7)
cm, p = 0.49] (Figure 1). The changes between adult height SDS
or near adult height SDS and height SDS at the beginning of the
study were also similar between the groups [Lz: −0.22 (0.8) and
Pl:−0.27 (0.7), p= 0.97].
Then, we compared the adult height or near adult height to
the PAH at the beginning of the study. In both groups, the adult
heights were similar to the PAHs at start of the study [Pl: 163.7
(3.7) cm vs. 166.9 (3.3), p= 0.06; Lz: 164.8 (4.0) cm vs. 167.6 (7.9),
p = 0.20, respectively]. The difference between adult height or
near adult height and PAH at the beginning was similar between
the Lz [−2.8 (5.1) cm] and the Pl groups [−3.2 (4.5) cm, p =
0.65]. Further, in both groups, adult or near adult height SDSs
FIGURE 1 | Adult heights and near adult heights (striped circles) of 20 boys
with idiopathic short stature who were treated with letrozole (Lz) or placebo (Pl)
for 2 years during pre and early puberty. Horizontal black lines represent
means and the p-value shows the between group comparison significance.
Lz, letrozole; Pl, placebo.
were significantly lower than the target heights [Lz, n = 10: −2.0
(0.6) SDS, p = 0.005 and Pl, n = 8: −2.4 (0.5) SDS, p = 0.012],
and no difference in adult or near adult height minus target
height was found between the groups [−2.0 (0.6) vs. −2.4 (0.5)
SDS, p = 0.32]. In the Lz group, only five boys progressed in
puberty during the treatment, and had similar adult height or
near adult height with those who remained prepubertal (n = 5)
[164.3 (4.0) vs. 165.5 (4.5) cm, p = 0.63, respectively]. Moreover,
the difference between adult height or near adult height and PAH
at the beginning was similar between pubertal Lz-treated boys
[0.5 (1.9) cm] and the Pl group [−3.4 (4.9) cm, p= 0.098]. In the
Lz group, the boys who progressed in puberty hadmore advanced
bone age than the Pl-boys at the end of the treatment [Lz; 12.9
(0.4) vs. 11.5 (1.3) years, p = 0.028]. Of note, bone ages at the
start of the study did not correlate with adult or near adult heights
(rs =−0.12, p= 0.62).
Vertebral Morphology
Five mildly deformed vertebral bodies were found in three
patients, two in Lz and one in Pl group (Table 2). The frequency
of vertebral deformities, intervertebral disk and endplate
abnormalities were similar between the groups (Table 2). Then
we compared the MRI findings to the results from the post-
treatment visit (9). Of the five boys with Lz who had vertebral
deformities detected before (9), three were re-evaluated withMRI
at the adult height visit. In one Lz-treated boy, the previously
reported vertebral deformity was visible in the adult height
visit MRI, whereas the previously reported mild deformities
(2a and 3a) in the other two Lz-treated boys had normalized.
Interestingly, one patient with Pl had developed a mild (grade 3a)
deformity in Th5 vertebral body. The absolute risk increase of
Lz-treatment for vertebral deformity was 17.5% (95% CI −21.8
to 56.7) and NNH was 6. Both treatment groups had similar
average psoas muscle thicknesses [Lz: 42.1 (5.9) mm and Pl:
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TABLE 2 | Vertebral morphology in 16 boys with idiopathic short stature at
completion or near completion of growth (bone age over 17 years) as evaluated
by MRI.
Lz (n = 7) Pl (n = 9) P-value*
Patients with vertebral
deformity (n)
2 1 0.55
Deformed vertebrae (n) 4 1 0.32
Grade 2a 2 1
Grade 2b
Grade 3a 2
Grade 3b
Patients with endplate
abnormalities (n)
2 4 0.63
Endplate abnormalities (n) 15 30
Patients with intervertebral
disk abnormalities (n)
2 2 0.92
Deformed vertebrae are classified based on the classification for pediatric vertebral body
morphology (15). *P-values are for between group comparisons analyzed with Fisher’s
exact test.
41.4 (5.9) mm, p = 0.81]. Two Pl-treated boys reported mild
exercise-related lumbar back pain.
Comorbidities
Seven of the 30 boys had a comorbidity that had required medical
attention. Comorbidities included depression, psychosis, chronic
fatigue syndrome, ulcerative colitis, and operated maxillary
hypoplasia. Interestingly, 5 of the 7 patients had a psychiatric
disease and antidepressant (n = 3) or antipsychotic (n =
2) medication. The frequency of subjects with psychiatric
comorbidity, however, did not differ significantly between those
who were treated with Lz (n = 4) and those who received Pl
(n= 1, p= 0.34).
DISCUSSION
In this follow-up study of our previously conducted placebo-
controlled randomized trial (1), we found that the pre- and
early-pubertal boys, who were previously treated for 2 years
with an AI, had similar adult heights with those who received
Pl. The boys treated with Lz had approximately 1.1 cm higher
adult heights than the subjects treated with Pl, which is neither
statistically nor clinically relevant. Thus, since this is the first
report on the impact of AI therapy on adult height in short boys
in a placebo-controlled randomized setting, the hard evidence
that would support the long-term growth-promoting effects of
aromatase inhibition is still lacking. This is a disappointment,
since previous RCTs have shown that treatment with 3rd
generation AIs effectively delays bone maturation and increases
PAH by 5.1–6.7 cm during 1–3 years of treatment in boys with
ISS, CDGP, or GHD, while allowing puberty to continue at
a normal rate (1, 2, 4). Based on these findings, the off-label
use of AIs in growth indications has expanded despite the lack
of evidence on long-term efficacy (i.e., adult height gain). Our
results indicate that, in boys with ISS, the beneficial effect of
a potent AI monotherapy given during pre- or early-puberty
is attenuated by later growth and maturation. This, however,
does not rule out a beneficial effect of AI-therapy on adult
height if the intervention is targeted exclusively to pubertal boys,
and the treatment is continued until late stages of puberty.
Only studies that follow subject to adult height will reveal the
effectiveness of AI- and other treatments aimed at increasing
adult height. To this end, in boys with CDGP, a short 12-
month co-treatment with Lz resulted in higher adult height
with borderline statistical significance than the treatment with
testosterone alone (4, 9). Further, when compared with GH
alone, 36 months of combined therapy with anastrozole and
GH significantly increased PAH in boys with GHD, who were
followed up until late stages of puberty with a mean bone age
of 17.2 years (2). Both of these studies, however, suffered from
significant dropout rates during follow-up, which increases the
risk of attrition bias. A recent study in boys with ISS, which
compared AI, GH, and their combination, reported favorable
near adult heights (mean bone age of 15.3 years) in subjects
treated with the combination (3). However, this study had no
placebo-treated control group, and no statistical comparison of
near adult height between AI plus GH and GH monotherapy
groups, which hampers drawing further conclusions on the
impact AI therapy on height outcome.
Our results on spine MRIs are reassuring and suggest that
2 years of AI-treatment in prepuberty or early puberty is not
detrimental to spine health in the long-term. We reported
previously that mild vertebral body abnormalities were detected
in five out of 11 (45%) participants assigned to Lz, whereas
there were none in the Pl group (9). This raised the concern
that Lz might disturb the normal growth and development of
vertebral bodies. Further, the deformities were found only in
boys who received Lz before the onset of puberty. In this study,
we showed that these deformities had normalized in two out
of three subjects with available long-term follow-up data. At
completion of growth (i.e., bone age above 17 years), significant
differences in vertebral parameters between the groups were
no longer evident. At the same time, we acknowledge that
our study has a small sample size, and a larger samples size
might yield a statistical significance. Our finding is in line
with previous studies with anastrozole and supports the view
that aromatase inhibitor treatment does not increase the risk
of vertebral deformities in the long-term (3). Additionally, we
found that endplate deformities were equally frequent in both
groups (16). This is in agreement with the current knowledge
that endplate deformities are a relatively common finding among
adolescents as ∼5% of healthy adolescents have these changes in
spine MRI (17).
We found no significant difference in the frequency of
comorbidities between the Lz and Pl groups. Altogether, 22%
of the boys had an ascertained comorbidity that required
medical attention. Interestingly, the Lz-treated boys had higher
frequency (25%) of psychiatric comorbidity than the subjects
with Pl (7%), but the difference did not reach statistical
significance. To our knowledge, AI treatment in males has
not been associated with psychiatric morbidity. In primates,
Lz easily penetrates the blood-brain barrier (18), and there is
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evidence that in males AI treatment may modulate cognitive
capacity and increase risk-taking behavior (19). In Lz-treated
boys of this study, the treatment had no measurable impact
on cognitive performance (20), which supports the view
that AI treatment appears not be harmful to adolescent
cognitive development.
Aromatase inhibition removes the negative feedback of
estrogen on the hypothalamic-pituitary-gonadal axis, which
results in stimulated FSH secretion and advanced testicular
growth (1, 21). Testicular size is known to correlate well
with sperm count (22). On the other hand, aromatase
knockout mice develop impairment of spermatogenesis,
and in men with congenital aromatase deficiency semen
samples have ranged from normal to oligospermia (23, 24).
Our finding that the Lz-treated subjects had similar adult
testicular volumes with their peers with Pl supports the
view that AI-treatment during pre- and early-puberty
had no detrimental influence on spermatogenesis. In line
with this, a previous study found that boys with GHD
previously treated with AI had similar sperm concentration,
motility, and morphology to their healthy peers (25). Future
larger studies evaluating semen samples of AI-treated boys
are warranted.
Several patients were lost during the follow-up resulting
in limited sample size which may result in attrition bias and
influence the interpretation of the results. However, this is
the largest RCT to describe adult height in AI-treated boys
and our dropout rate is comparable to that of other RCTs
(2, 9). Arguing against significant attrition bias, the participants
with available adult height data had a similar increase in PAH
during treatment with the total population of Lz-treated boys
(1). It is of note that the PAH produced by Bailey-Pinneau
method over-estimated adult height by about 3 cm. This is a
documented feature of the method in boys with retarded bone
age [reviewed in (26)].
CONCLUSIONS
This study reported similar adult heights between patients who
were previously treated with Lz and those who received Pl,
which questions the adult height-promoting effect of pre- and
early-pubertal AI-monotherapy in boys with ISS. As half of the
patients on Lz remained prepubertal during the treatment, our
findings may not be generalizable to short boys treated until
late stages of puberty. A larger placebo-controlled RCT, targeted
to pubertal short boys, is needed to establish the efficacy of AI
therapy in promoting adult height. Lz-treatment had no long-
term detrimental association on spine vertebral morphology,
which supports the skeletal safety of AI therapy in boys
with ISS.
AUTHOR CONTRIBUTIONS
TV collected and analyzed data, drafted the initial manuscript,
and reviewed and revised the manuscript. ST-S designed the
study, analyzed the radiological data, and reviewed and revised
the manuscript. LK analyzed the radiological data, reviewed,
and revised the manuscript. TR analyzed data, reviewed, and
revised the manuscript. MH designed the study, designed the
data collection instruments, coordinated and supervised data
collection, carried out the initial analyses, reviewed, and revised
the manuscript. LD conceptualized and designed the study,
reviewed, and revised the manuscript. All authors approved the
final manuscript and agree to be accountable for all aspects of
the work.
FUNDING
The study was funded by the Foundation for Pediatric
Research and Helsinki and Uusimaa Hospital district
research funds.
REFERENCES
1. Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis
with a potent aromatase inhibitor increases predicted adult height
in boys with idiopathic short stature: a randomized controlled trial.
J Clin Endocrinol Metab. (2005) 90:6396–402. doi: 10.1210/jc.2005-
1392
2. Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport
R, Schwartz ID, et al. Anastrozole increases predicted adult height of
short adolescent males treated with growth hormone: a randomized,
placebo-controlled, multicenter trial for one to three years. J
Clin Endocrinol Metab. (2008) 93:823–31. doi: 10.1210/jc.2007-
1559
3. Mauras N, Ross JL, Gagliardi P, Yu YM,Hossain J, Permuy J, et al. Randomized
trial of aromatase inhibitors, growth hormone, or combination in pubertal
boys with idiopathic, short stature. J Clin Endocrinol Metab. (2016) 101:4984–
93. doi: 10.1210/jc.2016-2891
4. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A
specific aromatase inhibitor and potential increase in adult height in boys with
delayed puberty: a randomised controlled trial. Lancet. (2001) 357:1743–8.
doi: 10.1016/S0140-6736(00)04895-9
5. Neely EK, Kumar RB, Payne SL, Ranadive SA, Suchet DI. Letrozole vs
anastrozole for height augmentation in short pubertal males: first year
data. J Clin Endocrinol Metab. (2014) 99:4086–93. doi: 10.1210/jc.201
4-2432
6. Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, Shamshiri
A, Monfared MF, et al. A double-blind, placebo-controlled comparison
of letrozole to oxandrolone effects upon growth and puberty of
children with constitutional delay of puberty and idiopathic short
stature. Horm Res Paediatr. (2010) 74:428–35. doi: 10.1159/000
315482
7. McGrath N, O’Grady MJ. Aromatase inhibitors for short stature in male
children and adolescents. Cochrane Database Syst Rev. (2015) 8:CD010888.
doi: 10.1002/14651858
8. Wit JM, Hero M, Nunez SB. Aromatase inhibitors in pediatrics.
Nat Rev Endocrinol. (2011) 8:135–47. doi: 10.1038/nrendo.20
11.161
9. Hero M, Toiviainen-Salo S, Wickman S, Makitie O, Dunkel L. Vertebral
morphology in aromatase inhibitor-treated males with idiopathic short
stature or constitutional delay of puberty. J Bone Miner Res. (2010) 25:1536–
43. doi: 10.1002/jbmr.56
10. Pedrosa LF, de Oliveira JM, Thomé PRV, Kochi C, Damiani
D, Longui CA. Height increment and laboratory profile of
boys treated with aromatase inhibitors with or without growth
hormone. Horm Metab Res. (2017) 49:778–85. doi: 10.1055/s-0043-
116944
Frontiers in Endocrinology | www.frontiersin.org 5 April 2019 | Volume 10 | Article 201
Varimo et al. Adult Height After Letrozole Treatment
11. Allen DB, Cuttler L. Clinical practice. Short stature in childhood–challenges
and choices. N Engl J Med. (2013) 368:1220–8. doi: 10.1056/NEJMcp1213178
12. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age:
revised for use with the greulich-pyle hand standards. J Pediatr. (1952)
40:423–41. doi: 10.1016/S0022-3476(52)80205-7
13. Hansen PF, With TK. Clinical measurements of the testes in
boys and men. Acta Med Scand Suppl. (1952) 266:457–65.
doi: 10.1111/j.0954-6820.1952.tb13395.x
14. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in
boys. Arch Dis Child. (1970) 45:13–23. doi: 10.1136/adc.45.239.13
15. Mäkitie O, Doria AS, Henriques F, Cole WG, Compeyrot S, Silverman E,
et al. Radiographic vertebral morphology: a diagnostic tool in pediatric
osteoporosis. J Pediatr. (2005) 146:395–401. doi: 10.1016/j.jpeds.2004.10.052
16. Hero M, Mäkitie O, Kröger H, Nousiainen E, Toiviainen-Salo S, Dunkel L.
Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth
and vertebral morphology in pre- and peripubertal boys with idiopathic short
stature. Horm Res. (2009) 71:290–7. doi: 10.1159/000208803
17. Ramadorai U, Hire J, DeVine JG, Brodt ED, Dettori JR. Incidental findings
on magnetic resonance imaging of the spine in the asymptomatic pediatric
population: a systematic review. Evid Based Spine Care J. (2014) 5:95–100.
doi: 10.1055/s-0034-1386753
18. Kil KE, Biegon A, Ding YS, Fischer A, Ferrieri RA, Kim SW, et al. Synthesis
and PET studies of [11C-cyano]letrozole (femara), an aromatase inhibitor
drug.Nucl Med Biol. (2009) 36:215–23. doi: 10.1016/j.nucmedbio.2008.11.010
19. Goudriaan AE, Lapauw B, Ruige J, Feyen E, Kaufman JM, Brand M, et al. The
influence of high-normal testosterone levels on risk-taking in healthy males
in a 1-week letrozole administration study. Psychoneuroendocrinology. (2010)
35:1416–21. doi: 10.1016/j.psyneuen.2010.04.005
20. Hero M, Maury S, Luotoniemi E, Service E, Dunkel L. Cognitive effects of
aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol. (2010)
163:149–55. doi: 10.1530/EJE-10-0040
21. Wickman S, Dunkel L. Inhibition of P450 aromatase enhances gonadotropin
secretion in early and midpubertal boys: evidence for a pituitary site
of action of endogenous E. J Clin Endocrinol Metab. (2001) 86:4887–94.
doi: 10.1210/jcem.86.10.7927
22. Jørgensen N, Joensen UN, Toppari J, Punab M, Erenpreiss J, Zilaitiene B, et al.
Compensated reduction in leydig cell function is associated with lower semen
quality variables: a study of 8182 European young men. Hum Reprod. (2016)
31:947–57. doi: 10.1093/humrep/dew021
23. Robertson KM, O’Donnell L, Jones ME, Meachem SJ, Boon WC, Fisher
CR, et al. Impairment of spermatogenesis in mice lacking a functional
aromatase (cyp 19) gene. Proc Natl Acad Sci USA. (1996) 96:7986–91.
doi: 10.1073/pnas.96.14.7986
24. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J,
et al. Effect of testosterone and estradiol in a man with aromatase
deficiency. N Engl J Med. (1997) 337: 91–5. doi: 10.1056/NEJM199707103
370204
25. Mauras N, Bell J, Snow BG, Winslow KL. Sperm analysis in growth
hormone-deficient adolescents previously treated with an aromatase
inhibitor: comparison with normal controls. Fertil Steril. (2005) 84:239–42.
doi: 10.1016/j.fertnstert.2005.02.012
26. Martin DD, Wit JM, Hochberg Z, Sävendahl L, van Rijn RR, Fricke O, et al.
The use of bone age in clinical practice—part 1. Horm Res Paediatr. (2011)
76:1–9. doi: 10.1159/000329372
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Varimo, Toiviainen-Salo, Raivio, Kerttula, Dunkel and Hero.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 6 April 2019 | Volume 10 | Article 201
